Literature DB >> 7718417

Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis.

W L Gross1, E Csernok.   

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) are a heterogeneous group of autoantibodies with a wide and diverse range of clinical associations. In vasculitis, the diagnostic utility of proteinase 3 (PR3)-ANCA and myeloperoxidase-ANCA for Wegener's granulomatosis and microscopic polyangiitis, respectively, is now well established. Because of their significance as tools for diagnosis and prognosis, these autoantibodies have been analyzed extensively as markers for underlying immunopathogenic disturbances. In this review, we consider recent advances in the understanding of ANCA, focusing on their detection, diagnostic value, and role in the pathogenesis of vasculitis. In addition, promising new ways have been developed to elucidate the pathophysiologic and diagnostic relevance of the ANCA target antigens PR3 and myeloperoxidase. A great deal of attention and controversy has focused on the possible mechanisms underlying the ANCA-related immune response, such as antigenic cross-reactivity between human polymorphonuclear leukocyte proteins and extrinsic antigens by molecular mimicry, idiotype network regulation, and T cell reactivity to PR3 and myeloperoxidase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718417

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  12 in total

1.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

2.  [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].

Authors:  A Schnabel; E Csernok; H Schultz; M Stoffel; C Herzberg; S F Carroll; W L Gross
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 3.  ANCA testing. New developments and clinical implications.

Authors:  A E Ahmed; J B Peter; Y Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  Joint disorders in cystic fibrosis.

Authors:  M A Turner; E Baildam; L Patel; T J David
Journal:  J R Soc Med       Date:  1997       Impact factor: 5.344

Review 5.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

6.  Defensins- and cathepsin G-ANCA in systemic lupus erythematosus.

Authors:  Hiroyuki Tamiya; Kenji Tani; Jyunya Miyata; Keiko Sato; Tomoyuki Urata; Battur Lkhagvaa; Shinsaku Otsuka; Shizuka Shigekiyo; Saburo Sone
Journal:  Rheumatol Int       Date:  2006-08-10       Impact factor: 2.631

7.  A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide.

Authors:  J Sun; D N Fass; M A Viss; A M Hummel; H Tang; H A Homburger; U Specks
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Specificities of anti-neutrophil autoantibodies in patients with rheumatoid arthritis (RA).

Authors:  J Brimnes; P Halberg; S Jacobsen; A Wiik; N H Heegaard
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 9.  Autoantibodies in vasculitis.

Authors:  Allan Wiik
Journal:  Arthritis Res Ther       Date:  2003-04-09       Impact factor: 5.156

10.  MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature.

Authors:  Mário Góis; Ana Messias; Dulce Carvalho; Fernanda Carvalho; Helena Sousa; João Sousa; Fernando Nolasco
Journal:  J Nephropathol       Date:  2016-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.